Outside melasma, the sources used here include a 1975 report, an open-label study, a laser comparison and a few randomized comparisons. The randomized trials compare hydroquinone 4% cream with 4% niacinamide cream or 5% ascorbic acid cream, and a hydroquinone 4%/ascorbic acid 3% cream with cysteamine 5%. The sources used here report no trial of hydroquinone 8% or of a blend with tretinoin, niacinamide and vitamin C.
Older and open-label reports
A 1975 report in Archives of Dermatology says a formula of tretinoin, hydroquinone and dexamethasone "was therapeutically effective" in melasma, ephelides and postinflammatory hyperpigmentation, while senile lentigines were resistant to it. The abstract gives no study design or number of participants, and the text used here does not give strengths.
An open-label study in melasma and postinflammatory hyperpigmentation used microentrapped HQ 4% with retinol 0.15%. No comparison group is described, and the abstract's conclusion is that it was safe and effective. Reports like these cannot show cause and effect.
Solar lentigines: laser versus a triple combination cream
A prospective trial compared a Q-switched ruby laser (QSRL) with a triple combination therapy (TCT) in solar lentigines. The abstract concludes that both were capable in reducing solar lentigines in Fitzpatrick skin Type I to IV with an acceptable side effect profile, and that the QSRL provides faster, superior, and long lasting lightening compared with TCT. The abstract does not mention randomization, and the text used here does not name the cream's ingredients or strengths.
The prescribing information for the approved fluocinolone acetonide, hydroquinone and tretinoin cream (0.01%;4%;0.05%) states that its safety and efficacy in hyperpigmentation conditions other than melasma of the face have not been studied.
Split-face and randomized comparisons
| Comparison | Design and size | Reported results |
|---|---|---|
| 4% niacinamide cream versus 4% HQ cream, melasma | Double-blind, randomized, one side of the face each; twenty-seven patients; eight weeks | Colorimetric measures showed no statistical differences. Good to excellent improvement: 44% with niacinamide, 55% with HQ. Side effects: 18% with niacinamide, 29% with HQ |
| 5% ascorbic acid cream versus 4% hydroquinone cream, idiopathic melasma | Double-blind, randomized, one side of the face each; sixteen women; used at night for 16 weeks | Best subjective improvement on the hydroquinone side: 93% good and excellent versus 62.5% (P < 0.05). Colorimetric measures showed no statistical differences. Side-effects: 68.7% (11/16) with hydroquinone, 6.2% (1/16) with ascorbic acid |
| Cysteamine 5% versus hydroquinone 4%/ascorbic acid 3% (HC) cream, acne-induced post-inflammatory hyperpigmentation | Randomized, controlled; the text used here gives no participant number | Both significantly decreased the PAHPI score and melanin index (p<0.05), with no significant difference between groups after four months (p>0.05) |
The disclosure for the cysteamine trial states that a named person is a shareholder of Scientis SA in Switzerland.
Other options sources mention
The MedlinePlus Skin Pigmentation Disorders topic links to pages on chemical peels, dermabrasion and laser resurfacing.
A Delphi consensus of dermatologists under the Pigmentary Disorders Society reports in its abstract key recommendations of regulated and supervised use of hydroquinone-based triple combination creams as the gold standard, and alternatives such as topical azelaic acid, kojic acid and oral tranexamic acid. Its abstract adds that chemical peels and microneedling were suggested to enhance topical efficacy, while lasers were reserved for refractory cases. An evidence-based review concluded that hydroquinone monotherapy and triple combination cream are the most effective and well-studied treatments for melasma, whereas chemical peels and laser- and light-based therapies are equal or inferior to topicals but offer a higher risk of adverse effects. The same review lists heterogeneity of study design, small sample size and lack of long-term follow-up as limitations of the evidence.
What this does not tell you
Some of these reports are old or open-label, the split-face trials had twenty-seven and sixteen patients, and some abstracts do not give strengths or sample sizes. Observational reports cannot show cause and effect. Comparisons at 4% hydroquinone, or with ascorbic acid at 3%, do not show how an 8% cream or a four-ingredient blend would perform, and the sources used here report no trial of either. Guidelines and consensus statements are summarized here only as far as their abstracts go. A licensed provider decides which option suits a person.